How Does AbbVie’s RA Drug Rinvoq Compare to Competitors?

AbbVie has announced that the Food and Drug Administration (FDA) approved its rheumatoid arthritis (RA) drug Rinvoq (upadacitinib). Rinvoq is an oral Janus kinase (JAK) inhibitor designed for the treatment of moderate to severe RA in patients who did not respond or have an intolerance to methotrexate. The company reported that the JAK inhibitor will … Continue reading How Does AbbVie’s RA Drug Rinvoq Compare to Competitors?